Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab

Leukemia volume 19, pages 1993–1995 (2005)Cite this article

TO THE EDITOR

Patients with angioimmunoblastic T-cell lymphoma (AITL) have a poor prognosis following conventional cytotoxic chemotherapy. With median remission rates of up to 50% achieved by combination chemotherapy, the probability of relapse is great, resulting in a median survival time of 36 months, with a range between 2 and 108 months.1

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 3
Figure 2

References

  1. Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999; 32: 545–552.

    Article  CAS  Google Scholar 

  2. Attygalle A, Al Jehani R, Diss TC, Munson P, Liu H, Du MQ et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 2002; 99: 627–633.

    Article  CAS  Google Scholar 

  3. Scappaticci FA . Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906–3927.

    Article  CAS  Google Scholar 

  4. Dogan A, Ngu LSP, Ng SH, Cervi PL . Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia 2005; 19: 873–875.

    Article  CAS  Google Scholar 

  5. Gasparini G, Longo R, Fanelli M, Teicher B . Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005; 23: 1295–1311.

    Article  CAS  Google Scholar 

  6. Hurwitz H, Fehrenbacher L, Cartwright T . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.

    Article  CAS  Google Scholar 

  7. Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legres L et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004; 84: 1512–1519.

    Article  CAS  Google Scholar 

  8. Wang E, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MAS . Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893–2902.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany

    I Bruns, F Fox, G Kobbe, R Kronenwett & R Haas

  2. Institut für Pathologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany

    P Reinecke

  3. Institut für Diagnostische Radiologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany

    G Jung

Authors
  1. I Bruns
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Reinecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Kobbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Kronenwett
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Bruns.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruns, I., Fox, F., Reinecke, P. et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 19, 1993–1995 (2005). https://doi.org/10.1038/sj.leu.2403936

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403936

This article is cited by

Search

Advanced search

Quick links